Skip to main content
VBIO
NASDAQ Life Sciences

3i, LP Sells 11.7M Shares and Converts Preferred Stock, Raising Stake to 9.9%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.179
Mkt Cap
$791.23K
52W Low
$0.159
52W High
$5.6
52W Position info
12% above low
Off High info
97% below high
Rel. Volume info
29× avg
Market data snapshot near publication time

VBIO is trading near its 52-week low of $0.159 (12% above the low) on elevated volume (29× avg).

Summary

Activist investor 3i, LP sold 11.7 million shares and converted preferred stock into 11.4 million new shares, raising its beneficial ownership to 9.9% of Valion Bio.


Key Events · Ownership and Investor Activity · VBIO

  • 3i, LP Sells 11.7M Shares

    On August 12, 2026, 3i, LP sold 11,676,430 shares of common stock at $0.3969 per share, generating approximately $4.6 million in proceeds.

  • Preferred Stock Conversions Add 11.4M Shares

    Between August 12 and 13, 2026, 3i, LP converted Series B and Series C preferred stock into 11,369,441 common shares at $0.39 per share, significantly increasing its equity stake.

  • Beneficial Ownership Reaches 9.9%

    After these transactions, 3i, LP's beneficial ownership stands at 1,742,699 shares, representing 9.9% of the outstanding common stock, just below the 10% threshold.

  • Activist Campaign Intensifies

    This filing follows 3i, LP's public demand for CEO removal and its proposed $9 million investment contingent on leadership changes, signaling an escalating proxy battle.


Analysis · VBIO · Life Sciences

The activist investor demanding CEO removal, 3i, LP, sold 11.7 million shares at $0.3969 while simultaneously converting preferred stock into 11.4 million new shares at $0.39. The net effect is a significant increase in beneficial ownership to 9.9% of the company, just below the 10% threshold that would trigger additional regulatory scrutiny. This move consolidates 3i's position as the largest shareholder and strengthens its leverage in the ongoing boardroom battle, while the sale of common shares at a price above the conversion price suggests a strategic rebalancing of its holdings.

At the time of this filing, VBIO was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $791.2K. The 52-week trading range was $0.16 to $5.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VBIO - Latest Insights

VBIO
Aug 14, 2026, 5:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.1794
Real-time Price: $0.1785 info
Change: -$0.0009 (-0.50%) info
Market Cap: $791.23K info
VBIO
Aug 11, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.3264
Real-time Price: $0.1785 info
Change: -$0.1479 (-45%) info
Market Cap: $791.23K info
VBIO
Aug 03, 2026, 7:01 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $0.3162
Real-time Price: $0.1785 info
Change: -$0.1377 (-44%) info
Market Cap: $791.23K info
VBIO
Jul 17, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.480
Real-time Price: $0.1785 info
Change: -$0.3015 (-63%) info
Market Cap: $791.23K info
VBIO
Jul 17, 2026, 4:01 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.5105
Real-time Price: $0.1785 info
Change: -$0.332 (-65%) info
Market Cap: $791.23K info